PubRank

Dan M Roden

Author PubWeight™ 323.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011 9.20
2 Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008 7.13
3 PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010 7.07
4 Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet 2010 6.44
5 ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 5.95
6 ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006 5.81
7 Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014 4.94
8 Implementing genomic medicine in the clinic: the future is here. Genet Med 2013 4.89
9 Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 2013 4.85
10 The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013 4.37
11 Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 2002 4.16
12 Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006 4.06
13 A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 4.02
14 Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010 3.97
15 A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet 2011 3.94
16 Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med 2016 3.88
17 Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet 2011 3.85
18 Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci 2010 3.84
19 Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012 3.71
20 Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009 3.35
21 Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation 2010 3.35
22 Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013 3.21
23 ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006 3.11
24 Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002 2.98
25 Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010 2.94
26 KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 2005 2.78
27 Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008 2.72
28 Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 2006 2.72
29 Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 2007 2.62
30 Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 2012 2.61
31 Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008 2.56
32 Drug-induced long QT syndrome. Pharmacol Rev 2010 2.55
33 Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008 2.54
34 ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006 2.54
35 Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010 2.49
36 Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 2.41
37 Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation 2007 2.38
38 Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007 2.32
39 Unmasking of brugada syndrome by lithium. Circulation 2005 2.30
40 Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003 2.28
41 Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med 2010 2.09
42 Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 2013 2.06
43 Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009 2.06
44 Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004 2.05
45 Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007 2.04
46 Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2008 1.99
47 Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009 1.92
48 Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm 2010 1.87
49 Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013 1.86
50 Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A 2006 1.85
51 When good drugs go bad. Nature 2007 1.85
52 Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol 2012 1.84
53 A calcium sensor in the sodium channel modulates cardiac excitability. Nature 2002 1.83
54 Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest 2004 1.80
55 Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol 2008 1.77
56 Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011 1.77
57 Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm 2010 1.77
58 Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 2007 1.73
59 The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008 1.69
60 Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc 2011 1.67
61 Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm 2011 1.66
62 Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012 1.66
63 Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol 2003 1.65
64 Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm 2005 1.63
65 Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res 2012 1.60
66 Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet 2009 1.59
67 Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm 2005 1.58
68 Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. Heart Rhythm 2006 1.57
69 Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 2002 1.57
70 Mutations in sodium channel β1- and β2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2009 1.56
71 ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm 2009 1.55
72 The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther 2013 1.50
73 Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med 2013 1.48
74 A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2011 1.48
75 Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation 2005 1.48
76 A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet 2013 1.47
77 Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005 1.45
78 A genetic framework for improving arrhythmia therapy. Nature 2008 1.45
79 Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS One 2011 1.42
80 Leveraging the electronic health record to implement genomic medicine. Genet Med 2012 1.42
81 An analytical approach to characterize morbidity profile dissimilarity between distinct cohorts using electronic medical records. J Biomed Inform 2010 1.42
82 Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009 1.41
83 Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 2009 1.41
84 Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation 2011 1.38
85 Modulators of normal electrocardiographic intervals identified in a large electronic medical record. Heart Rhythm 2010 1.35
86 Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med 2014 1.32
87 Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol 2009 1.31
88 Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 2013 1.30
89 Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation 2012 1.26
90 Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm 2012 1.23
91 Atrial fibrillation in KCNE1-null mice. Circ Res 2005 1.21
92 Repolarization reserve: a moving target. Circulation 2008 1.20
93 Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics 2009 1.16
94 A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. Ann Emerg Med 2010 1.15
95 Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012 1.15
96 Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation 2005 1.14
97 Voltage-gated sodium channels are required for heart development in zebrafish. Circ Res 2010 1.14
98 High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin Transl Sci 2012 1.13
99 New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation 2005 1.12
100 Defective human Ether-à-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem 2002 1.12
101 Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol 2013 1.11
102 Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. Am J Cardiol 2012 1.10
103 Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005 1.10
104 Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2003 1.09
105 Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions. Circulation 2003 1.09
106 A structural requirement for processing the cardiac K+ channel KCNQ1. J Biol Chem 2004 1.08
107 In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A 2004 1.07
108 Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009 1.06
109 A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012 1.06
110 Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002 1.05
111 Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm 2013 1.04
112 Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One 2013 1.04
113 Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol 2012 1.01
114 Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. G3 (Bethesda) 2013 1.00
115 Data re-identification: societal safeguards. Science 2013 0.99
116 Drug therapy for atrial fibrillation: where do we go from here? Nat Rev Drug Discov 2005 0.99
117 Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans. Ann Hum Genet 2013 0.99
118 Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. J Cardiol 2011 0.98
119 A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 2012 0.97
120 Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol 2008 0.97
121 [Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. Rev Esp Cardiol 2006 0.96
122 Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pac Symp Biocomput 2006 0.96
123 Modeling drug exposure data in electronic medical records: an application to warfarin. AMIA Annu Symp Proc 2011 0.96
124 Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol 2007 0.96
125 Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol 2009 0.95
126 The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J 2003 0.95
127 Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous system. Cardiovasc Res 2002 0.94
128 Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther 2005 0.94
129 Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome. Pediatr Res 2003 0.93
130 SCN5A variation is associated with electrocardiographic traits in the Jackson Heart Study. Circ Cardiovasc Genet 2011 0.93
131 Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc Res 2004 0.93
132 Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. Dis Model Mech 2012 0.93
133 Recombinase-mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis 2006 0.93
134 Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest 2005 0.93
135 Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002 0.92
136 Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One 2012 0.92
137 Systems biology and cardiac arrhythmias. Lancet 2012 0.92
138 Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics 2013 0.91
139 A connexin40 mutation associated with a malignant variant of progressive familial heart block type I. Circ Arrhythm Electrophysiol 2012 0.91
140 Visual integration of results from a large DNA biobank (BioVU) using synthesis-view. Pac Symp Biocomput 2011 0.91
141 Brugada-type ECG pattern and extreme QRS complex widening with propafenone overdose. J Cardiovasc Electrophysiol 2006 0.91
142 Refining repolarization reserve. Heart Rhythm 2011 0.90
143 Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates. BMC Evol Biol 2007 0.90
144 Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One 2011 0.90
145 Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003 0.90
146 Enabling genomic-phenomic association discovery without sacrificing anonymity. PLoS One 2013 0.89
147 Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. Europace 2013 0.89
148 Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol 2003 0.88
149 A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol 2007 0.88
150 Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 2014 0.88
151 Whole exome sequencing identifies a causal RBM20 mutation in a large pedigree with familial dilated cardiomyopathy. Circ Cardiovasc Genet 2013 0.87
152 An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005 0.86
153 A surprising new arrhythmia mechanism in heart failure. Circ Res 2003 0.86
154 The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 2009 0.86
155 Future of antiarrhythmic drugs. Curr Opin Cardiol 2006 0.85
156 Autonomic tone attenuates drug-induced QT prolongation. J Cardiovasc Electrophysiol 2007 0.85
157 Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development. Development 2013 0.84
158 A genotype-dependent intermediate ECG phenotype in patients with persistent lone atrial fibrillation genotype ECG-phenotype correlation in atrial fibrillation. Circ Arrhythm Electrophysiol 2009 0.84
159 An allosteric mechanism for drug block of the human cardiac potassium channel KCNQ1. Mol Pharmacol 2012 0.84
160 KCNH2 pharmacogenomics summary. Pharmacogenet Genomics 2010 0.84
161 Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine? Circulation 2013 0.83
162 Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation 2010 0.83
163 Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2012 0.82
164 Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I(Ks) block by protein kinase A-mediated I(Ks) phosphorylation. Br J Pharmacol 2009 0.82
165 Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 2004 0.81
166 Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients. Pac Symp Biocomput 2014 0.81
167 A new role for calmodulin in ion channel biology. Circ Res 2006 0.81
168 Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet 2016 0.80
169 Coinheritance of long QT syndrome and Kearns-Sayre syndrome. Heart Rhythm 2007 0.80
170 The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol 2002 0.80
171 Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. Circulation 2005 0.80
172 Brugada syndrome: lots of questions, some answers. Heart Rhythm 2010 0.80
173 Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol 2012 0.80
174 The molecular genetics of arrhythmias. Cardiovasc Res 2005 0.80
175 Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Circ Res 2011 0.79
176 Rate-independent QT shortening during exercise in healthy subjects: terminal repolarization does not shorten with exercise. J Cardiovasc Electrophysiol 2008 0.79
177 Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart Assoc 2012 0.79
178 Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med 2013 0.79
179 Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep 2013 0.79
180 QT variability during initial exposure to sotalol: experience based on a large electronic medical record. Europace 2013 0.79
181 Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm 2005 0.78
182 Left atrial hypertension after repeated catheter ablations for atrial fibrillation. J Am Coll Cardiol 2011 0.78
183 Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med 2013 0.78
184 Replication of SCN5A Associations with Electrocardio-graphic Traits in African Americans from Clinical and Epidemiologic Studies. Evol Comput Mach Learn Data Min Bioinform 2015 0.78
185 Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. Circ Cardiovasc Genet 2016 0.77
186 Ethical and practical challenges to studying patients who opt out of large-scale biorepository research. J Am Med Inform Assoc 2013 0.77
187 When should QT be measured? Summer solstice or Christmas Eve? Heart Rhythm 2006 0.77
188 Probing the arrhythmogenic substrate. Heart Rhythm 2006 0.77
189 Genome-wide assessment for genetic variants associated with ventricular dysfunction after primary coronary artery bypass graft surgery. PLoS One 2011 0.77
190 Transcription factor ETV1 is essential for rapid conduction in the heart. J Clin Invest 2016 0.77
191 Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother 2006 0.77
192 Cardiovascular effects of noncardiovascular drugs. Circulation 2009 0.76
193 Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics 2016 0.76
194 STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pac Symp Biocomput 2016 0.75
195 Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol 2010 0.75
196 Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics 2014 0.75
197 Genetic testing in subjects with no clinical abnormality: the tip of a huge iceberg. J Am Coll Cardiol 2011 0.75
198 A memorable experience. Europace 2007 0.75
199 Identification of unique venous thromboembolism-susceptibility variants in African-Americans. Thromb Haemost 2017 0.75
200 Fundamental Cardiovascular Research: Returns on Societal Investment: A Scientific Statement From the American Heart Association. Circ Res 2017 0.75
201 Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenet Genomics 2017 0.75
202 A shock in time. Clin J Sport Med 2007 0.75
203 Intracellular sodium overload: a system biology problem with implications for drug target identification. J Cardiovasc Electrophysiol 2006 0.75
204 Erratum: Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet 2017 0.75